 |
 |
Ms. Valenze: Thank you for your speedy response to my email. My inquiry, however, was mainly about the cost of this cancer drug and I understood that Novartis had a “compassionate”policy for a leukemia patient who couldn’t afford the drug. Dr. Brian Druker, who developed the drug informed me that the Leukemia and Lymphoma Society paid for his research. Since Novartis didn’t develop this drug, I was wondering how such an outrageous price of S120,000 a year could be justified. I understand Georgetown University Medical Center is planning on conducting further trials using Nilotinib for other neurodegenerative diseases such as Alzheimer’s, ALS, and Huntington’s. If Tasigna or Nilotinib does prove beneficial or even curative to Parkinson’s and/or other diseases, there is a billion dollar market for Novartis at S1 per pill. Why not be truly compassionate and lower the cost of this drug? How heartbreaking it would be if unaffordable cures were available and millions had to beg for them. Thanks again for your kind consideration of my plea. From: Valenze, Virginia Sent: Monday, October 26, 2015 12:21 PM To: [log in to unmask] Cc: Ericksen, Veronica ; SANDERSON, Ayo ; Frable, Anna ; JaffeNagler, Alissa Subject: Your Query Regarding Nilotinib Study Dear Ms. Brown, Thanks so much for your inquiry regarding the study on Parkinson’s Disease. We understand that the cost of medicines can be challenging for some patients. Novartis offers a significant patient Ray Rayilyn Brown Past Director AZNPF Arizona Chapter National Parkinson Foundation ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn